Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 10 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 22, 2018 Filed Mar 26, 2018 20:02 UTC |
Henderson JaneSr. V.P. & CFO, Corp. Dev.
|
Exercise / conversionCommon Stock | 19,900 | $11.97 | $238,203.00 |
DisclosureSEC source: 0001104659-18-020100 · a4.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 21:43 UTC |
Henderson JaneCFO & SVP, Corp. Dev.
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,900 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · derivative · entry 6 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,684 Underlying: Common Stock · 1,900 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 21:43 UTC |
Henderson JaneCFO & SVP, Corp. Dev.
|
SaleCommon Stock | 1,900 | $21.76 | $41,344.00 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · nonDerivative · entry 4 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $21.80, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 21:43 UTC |
Henderson JaneCFO & SVP, Corp. Dev.
|
Exercise / conversionCommon Stock | 1,900 | $11.97 | $22,743.00 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · nonDerivative · entry 3 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 21:43 UTC |
Henderson JaneCFO & SVP, Corp. Dev.
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,416 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · derivative · entry 5 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,584 Underlying: Common Stock · 15,416 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 21:43 UTC |
Henderson JaneCFO & SVP, Corp. Dev.
|
SaleCommon Stock | 15,416 | $22.15 | $341,464.40 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · nonDerivative · entry 2 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.42, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 21:43 UTC |
Henderson JaneCFO & SVP, Corp. Dev.
|
Exercise / conversionCommon Stock | 15,416 | $11.97 | $184,529.52 |
DisclosureSEC source: 0001104659-18-019018 · a4.xml · nonDerivative · entry 1 Henderson Jane · CIK 0001422304 · CFO & SVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:07 UTC |
Ravina BernardChief Medical Officer
|
SaleCommon Stock | 2,451 | $25.16 | $61,667.16 |
DisclosureSEC source: 0001104659-18-017480 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,451 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:12 UTC |
PAUL STEVEN MDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001104659-18-016417 · a4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over two years, with 1/24th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/24th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:12 UTC |
Ottmer Matthew P.Chief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001104659-18-016416 · a4.xml · derivative · entry 1 Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:12 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001104659-18-016415 · a4.xml · derivative · entry 1 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:11 UTC |
Ravina BernardChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001104659-18-016414 · a4.xml · derivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:11 UTC |
Henderson JaneSr. V.P. & CFO
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001104659-18-016413 · a4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,063 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · derivative · entry 9 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,937 Underlying: Common Stock · 4,063 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of February 8, 2017, and 1/48th of the shares underlying such option vesting monthly thereafter. This Form 4 also aggregates identical options which were reported separately on the reporting person's Form 3. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $11.09 | $0.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · derivative · entry 8 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 5,000 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of February 1, 2016, and 1/48th of the shares underlying such option vesting monthly thereafter. This Form 4 also aggregates identical options which were reported separately on the reporting person's Form 3. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,376 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · derivative · entry 7 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,570 Underlying: Common Stock · 4,376 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of August 1, 2015, and 1/48th of the shares underlying such option vesting monthly thereafter. This Form 4 also aggregates identical options which were reported separately on the reporting person's Form 3. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,184 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · derivative · entry 6 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,957 Underlying: Common Stock · 2,184 shares Expires 2025-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of January 1, 2015, and 1/48th of the shares underlying such option vesting monthly thereafter. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
SaleCommon Stock | 15,623 | $30.00 | $468,690.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 5 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 4,063 | $11.83 | $48,065.29 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 4 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 5,000 | $11.09 | $55,450.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 3 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 4,376 | $8.33 | $36,452.08 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 2 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC |
Sah Dinah Ph.D.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,184 | $7.27 | $15,877.68 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 1 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 13, 2018 21:10 UTC |
Ravina BernardChief Medical Officer
|
SaleCommon Stock | 2,451 | $18.24 | $44,706.24 |
DisclosureSEC source: 0001104659-18-009011 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,902 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 13:57 UTC |
Ravina BernardChief Medical Officer
|
SaleCommon Stock | 3,630 | $16.40 | $59,532.00 |
DisclosureSEC source: 0001104659-18-001967 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,353 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 21:02 UTC |
Ravina BernardChief Medical Officer
|
SaleCommon Stock | 5,490 | $13.63 | $74,828.70 |
DisclosureSEC source: 0001104659-17-073124 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,983 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.32 to $14.03, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 21:15 UTC |
Ravina BernardChief Medical Officer
|
SaleCommon Stock | 5,490 | $13.26 | $72,797.40 |
DisclosureSEC source: 0001104659-17-067963 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,473 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.50, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 23:28 UTC |
Ravina BernardChief Medical Officer
|
SaleCommon Stock | 10,980 | $20.33 | $223,223.40 |
DisclosureSEC source: 0001104659-17-062001 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,963 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.93 to $20.49, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 20:13 UTC |
Ottmer Matthew P.Chief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0001104659-17-057639 · a4.xml · derivative · entry 1 Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-09-14 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is September 11, 2017. The option vests over four years, with 25% of the shares of common stock underlying the option vesting upon the one-year anniversary of the Vesting Commencement Date and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 21:23 UTC |
Ravina BernardChief Medical Officer
|
SaleCommon Stock | 10,980 | $14.30 | $157,014.00 |
DisclosureSEC source: 0001104659-17-056988 · a4.xml · nonDerivative · entry 2 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,943 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.95, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. F3 · balance_after: This total reflects an adjustment for a clerical error on the reporting person's Form 3 wherein the number of shares beneficially owned was inadvertently overstated by 62,744 shares. Such shares were sold prior to Dr. Ravina becoming a reporting person. F5 · balance_after: This total reflects the number of shares beneficially owned by the reporting person as of the date hereof, following the reported transaction and inclusive of all intervening transactions. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 20:38 UTC |
Ravina BernardChief Medical Officer
|
SaleCommon Stock | 5,490 | $10.00 | $54,900.00 |
DisclosureSEC source: 0001104659-17-055821 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,157 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 20, 2017 Filed Sep 13, 2017 21:23 UTC |
Ravina BernardChief Medical Officer
|
SaleCommon Stock | 5,490 | $10.00 | $54,900.00 |
DisclosureSEC source: 0001104659-17-056988 · a4.xml · nonDerivative · entry 1 Ravina Bernard · CIK 0001711276 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,413 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: This total reflects the number of shares beneficially owned by the reporting person on July 20, 2017, following the reported transaction. F3 · balance_after: This total reflects an adjustment for a clerical error on the reporting person's Form 3 wherein the number of shares beneficially owned was inadvertently overstated by 62,744 shares. Such shares were sold prior to Dr. Ravina becoming a reporting person. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 16:03 UTC |
Levin Mark JDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042942 · a4.xml · derivative · entry 1 LEVIN MARK J · CIK 0001180428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Mr. Levin's continued service on the Board of Directors. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:03 UTC |
DIXON WENDY LDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042941 · a4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Ms. Dixon's continued service on the Board of Directors. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:02 UTC |
Higgins Michael JDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042940 · a4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Mr. Higgins' continued service on the Board of Directors. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:02 UTC |
GERAGHTY JAMES ADirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042939 · a4.xml · derivative · entry 1 GERAGHTY JAMES A · CIK 0001239746 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Mr. Geraghty's continued service on the Board of Directors. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:02 UTC |
KARSEN PERRY ADirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042938 · a4.xml · derivative · entry 1 KARSEN PERRY A · CIK 0001260573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Mr. Karsen's continued service on the Board of Directors. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:02 UTC |
Hyman StevenDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042937 · a4.xml · derivative · entry 1 Hyman Steven · CIK 0001656506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Mr. Hyman's continued service on the Board of Directors. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:02 UTC |
PIERCE GLENNDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001104659-17-042936 · a4.xml · derivative · entry 1 PIERCE GLENN · CIK 0001256964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Mr. Pierce's continued service on the Board of Directors. Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 16:00 UTC |
Levin Mark JDirector · 10% owner
|
OtherCommon Stock | 920,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-010310 · doc4.xml · nonDerivative · entry 1 LEVIN MARK J · CIK 0001180428 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,391,176 F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on April 12, 2017, for no consideration, 920,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on April 12, 2017, for no consideration, 920,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 20:00 UTC |
Third Rock Ventures III, L.P.10% owner
Third Rock Ventures GP III, L.P.10% owner
TRV GP III, LLC10% owner
STARR KEVIN P10% owner
Tepper Robert I10% owner
|
OtherCommon Stock | 920,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-010312 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,391,176 F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on April 12, 2017, for no consideration, 920,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on April 12, 2017, for no consideration, 920,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 21:01 UTC |
PAUL STEVEN MDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 240,000 | $11.83 Strike: $11.83 | $2,839,200.00 |
DisclosureSEC source: 0001104659-17-008172 · a4.xml · derivative · entry 1 PAUL STEVEN M · CIK 0001237564 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2027-02-08 F1 · derivative.exercise_date: This stock option award was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan and will vest in 48 equal monthly installments from grant date. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:26 UTC |
Henderson JaneSr. V.P. & CFO
|
GrantStock Option (Right to Buy) · Derivative | 214,000 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-17-000985 · a4.xml · derivative · entry 1 Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,000 Underlying: Common Stock · 214,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: These stock options were issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. 53,500 of the shares of common stock underlying the options will vest on 1/1/2018 and the remainder will vest in 36 equal monthly installments thereafter, subject to continued service. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:26 UTC |
PIERCE GLENNDirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-17-000984 · a4.xml · derivative · entry 1 PIERCE GLENN · CIK 0001256964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: These stock options were issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The shares of common stock underlying the options will vest in quarterly installments subject to continued service. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 22:25 UTC |
DIXON WENDY LDirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001104659-17-000983 · a4.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: These stock options were issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The shares of common stock underlying the options will vest in quarterly installments subject to continued service. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 17:51 UTC |
Levin Mark JDirector · 10% owner
|
OtherCommon Stock | 750,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-036196 · doc4.xml · nonDerivative · entry 1 LEVIN MARK J · CIK 0001180428 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,311,176 F1 · kind: On December 19, 2016, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 750,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On December 19, 2016, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 750,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 22:49 UTC |
Third Rock Ventures III, L.P.10% owner
Third Rock Ventures GP III, L.P.10% owner
TRV GP III, LLC10% owner
STARR KEVIN P10% owner
Tepper Robert I10% owner
|
OtherCommon Stock | 750,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-036195 · doc4.xml · nonDerivative · entry 1 Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner TRV GP III, LLC · CIK 0001637299 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,311,176 F1 · kind: On December 19, 2016, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 750,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On December 19, 2016, Third Rock Ventures III, L.P. ("TRV III") distributed, for no consideration, 750,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP III, L.P. ("TRV GP III"), the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.